List of Noxafil drug patents

Noxafil is owned by Schering.

Noxafil contains Posaconazole.

Noxafil has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Noxafil are:

  • US8263600

Noxafil was authorised for market use on 15 September, 2006.

Noxafil is available in suspension;oral dosage forms.

The generics of Noxafil are possible to be released after 01 April, 2022.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8263600 SCHERING Antifungal composition with enhanced bioavailability
Apr, 2022

(1 year, 2 months ago)

Do you want to check out NOXAFIL patents from before 2022?

Drugs and Companies using POSACONAZOLE ingredient

Market Authorisation Date: 15 September, 2006

Treatment: NA

Dosage: SUSPENSION;ORAL

How can I launch a generic of NOXAFIL before it's patent expiration?
More Information on Dosage

NOXAFIL family patents

4

United States

2

Australia

2

Japan

2

European Union

1

Canada

1

Mexico

1

Argentina

1

Brazil

1

China

1

New Zealand

1

South Africa

1

Hungary

1

Poland

1

Peru

1

Norway

1

Taiwan

1

Korea, Republic of

Noxafil is owned by Merck Sharp Dohme.

Noxafil contains Posaconazole.

Noxafil has a total of 6 drug patents out of which 0 drug patents have expired.

Noxafil was authorised for market use on 13 March, 2014.

Noxafil is available in solution;intravenous dosage forms.

Noxafil can be used as treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; prophylaxis of invasive aspergillus and candida infections; prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised, treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised.

The generics of Noxafil are possible to be released after 27 February, 2033.

NOXAFIL's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750822 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US10117951 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US8410077 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9358297 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin
Jun, 2031

(8 years from now)

US9023790 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin
Jul, 2031

(8 years from now)

US9493582 MERCK SHARP DOHME Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(9 years from now)

Do you want to check out NOXAFIL patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) May 31, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2028
New Indication (I) Jun 17, 2024

Drugs and Companies using POSACONAZOLE ingredient

Market Authorisation Date: 13 March, 2014

Treatment: Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of a...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of NOXAFIL before it's patent expiration?
More Information on Dosage

NOXAFIL family patents

19

United States

9

Japan

7

China

6

European Union

5

Korea, Republic of

5

Mexico

4

Australia

4

Canada

3

Russia

2

Israel

2

Hong Kong

2

Brazil

EA

1

EA

1

Croatia

1

New Zealand

1

Denmark

1

Spain

1

Portugal

1

Poland

1

Slovenia

1

RS

1

Hungary

1

Lithuania

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in